Osteoporosis Treatment Strategies and Counseling Pearls for Pharmacists, featuring Pharmacist-Patient Counseling Vignettes

Osteoporosis Treatment Strategies and Counseling Pearls for Pharmacists, featuring Pharmacist-Patient Counseling Vignettes

Faculty Presenters

Liza W. Claus, PharmD, BCACP
Assistant Professor
Department of Clinical Pharmacy
University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences
Aurora, Colorado

Medical Writer for Patient Counseling Videos

Ron Gasbarro, PharmD, MSJourn
Principal
Rx-Press
New Milford, Pennsylvania
 
Program Description
Individuals with osteoporosis experience bone fragility and are more susceptible to fractures. Osteoporosis is more prevalent in women of older age due to transitions in hormone production that occur during menopause, and nearly 1.4 million fractures occur in women in the United States each year due to osteoporosis. While less common in men, osteoporosis does pose a significant public health burden in this population due to rising cases as life expectancy increases. Any type of fracture, particularly hip, vertebral, and wrist fractures, can incur substantial health care burden and significantly interfere with a patient’s quality of life and ability to perform activities of daily living. These factors are important for pharmacists to consider when communicating with patients who may be at increased risk or are diagnosed with osteoporosis. With an understanding of screening recommendations and both nonpharmacologic strategies as well as pharmacologic therapies for osteoporosis, pharmacists can be influential in osteoporosis management. This activity will provide specialty pharmacists with the most recent data related to osteoporosis prevention and treatment modalities and a review of the recently updated AACE guidelines. The counseling video vignettes included in this activity will detail approaches pharmacists can use to engage patients in discussion about prevention, treatment and management of this condition.

Target Audience: Health-system pharmacists, retail pharmacists, and specialty pharmacists 
Type of Activity: Application
Release date: March 10, 2021
Expiration date: March 10, 2022
Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives
At the completion of this activity, participants will be able to:

• Classify the epidemiology, etiology, and pathophysiology of osteoporosis as well as the clinical and economic burden and associated evidence-based screening and diagnostic recommendations
• Explore the role of current and recently approved therapies, such as abaloparatide and romosozumab, in osteoporosis treatment, including mechanism of action, efficacy, safety, and place in therapy based on the 2020 AACE/ACE guidelines
• Identify the role of the pharmacist in improving communication between patients and health care providers and recognizing those who may be at risk for osteoporosis and osteoporotic fractures

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-21-109-H01-P. The activity is available for CE credit through March 10, 2022.


Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
 

---

Disclosures

Liza W. Claus, PharmD, BCACP and Ron Gasbarro, PharmD, MSJourn have no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ Planning Staff – Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Rose Namissa, PharmD, BCPS, Brianna Schauer, MBA, PMP; Crissy Wilson; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose.

An anonymous peer reviewer is used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms